Exagen Inc. to Participate in December Investor Conferences
November 18 2020 - 4:05PM
Exagen Inc. (Nasdaq: XGN), an organization dedicated to
transforming the care continuum for patients suffering from
autoimmune diseases, announced today that company management will
participate in the following December investor conferences:
- Piper Sandler
32nd Annual Virtual Healthcare
Conference, November 30 – December 3, 2020A recorded
company presentation will be available via the Piper Sandler
conference site from November 23 to December 3, and on the Exagen
website at: https://investors.exagen.com/events
- Evercore ISI
3rd Annual
HealthCONx Conference, December 1-3,
2020Exagen President and CEO Ron Rocca will participate in
a Fireside Chat on Wednesday, December 2, 2020, at 10:30 am EST. A
link to the live webcast of the Fireside Chat will be posted to the
Exagen website at: https://investors.exagen.com/events
About Exagen Inc.
Exagen is dedicated to transforming the care
continuum for patients suffering from debilitating and chronic
autoimmune diseases by enabling timely differential diagnosis and
optimizing therapeutic intervention. Exagen has developed
and is commercializing a portfolio of innovative testing products
under its AVISE® brand. Several of these products are based on our
proprietary Cell-Bound Complement Activation Products, or CB-CAPs,
technology. CB-CAPs assess the activation of the complement system,
a biological pathway implicated in systemic lupus erythematosus, or
SLE. Exagen’s goal is to enable rheumatologists to improve care for
patients through the differential diagnosis, prognosis and
monitoring of complex autoimmune and autoimmune-related diseases,
including SLE and rheumatoid arthritis, or RA. Exagen’s model of
integrating testing products and therapeutics
positions Exagen to offer targeted solutions to
rheumatologists and, ultimately, better serve patients. For
more information, please visit www.Exagen.com.
InvestorsWestwicke PartnersMike
CavanaughMike.Cavanaugh@westwicke.com 646.677.1838
CompanyExagen Inc.Kamal Adawi,
Chief Financial Officerkadawi@exagen.com760.477.5514
Exagen (NASDAQ:XGN)
Historical Stock Chart
From Aug 2024 to Sep 2024
Exagen (NASDAQ:XGN)
Historical Stock Chart
From Sep 2023 to Sep 2024